Randomized Controlled Trial for H.pylori third line eradication therapy: PPI vs PCAB

Randomized Controlled Trial for H.pylori third line eradication therapy: PPI vs PCAB - PCAB-based H.pylori third line eradication study (CAP-3 study)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016336

Enrollment

126

Registered

2015-02-01

Start date

2015-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori infection

Interventions

sitafloxacin(STFX) +amoxicillin(AMPC)+ P-CAB sitafloxacin(STFX) +amoxicillin(AMPC)+ PPI

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: First line eradication(PPI+AMPC+CAM) and second line eradication(PPI+AMPC+MNZ) failure patients with H.pylori infection who want to take eradication treatment. Patients who give a written informed consent.

Exclusion criteria

Exclusion criteria: Pregnancy or lactation. Past history of allergy for the drugs used in this therapy. Severe liver dysfunction, Severe renal dysfunction, Severe heart dysfunction. Patients who are disqualified for the study by physicians.

Design outcomes

Primary

Measure	Time frame
Comparison of third line H.pylori eradication rate of the two regimens, sitafloxacin(STFX) +amoxicillin(AMPC)+ P-CAB vs sitafloxacin(STFX) +amoxicillin(AMPC)+ PPI	—

Secondary

Measure	Time frame
Comparison of Safety of the two regimens, sitafloxacin(STFX) +amoxicillin(AMPC)+ P-CAB vs sitafloxacin(STFX) +amoxicillin(AMPC)+ PPI	—

Countries

Japan

Contacts

Public ContactSoichiro Sue

Yokohama City University Hospital Gastroenterology

ssue@yokohama-cu.ac.jp045-261-5656

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026